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ABSTRACT: Citrate lyase (EC 4.1.3.6) catalyzes the cleavage of citrate to acetate and oxaloacetate and is
composed of three subunits (R, â, and ç). The ç-subunit serves as an acyl carrier protein (ACP) and
contains the prosthetic group 2′-(5′′-phosphoribosyl)-3′-dephospho-CoA, which is attached via a
phosphodiester linkage to serine-14 in the enzyme from Klebsiella pneumoniae. In this work, we
demonstrate by genetic and biochemical studies with citrate lyase of Escherichia coli and K. pneumoniae
that the conversion of apo-ACP into holo-ACP is dependent on the two proteins, CitX (20 kDa) and CitG
(33 kDa). In the absence of CitX, only apo-ACP was synthesized in vivo, whereas in the absence of
CitG, an adenylylated ACP was produced, with the AMP residue attached to serine-14. The adenylyl-
transferase activity of CitX could be verified in vitro with purified CitX and apo-ACP plus ATP as
substrates. Besides ATP, CTP, GTP, and UTP also served as nucleotidyl donors in vitro, showing that
CitX functions as a nucleotidyltransferase. The conversion of apo-ACP into holo-ACP was achieved in
vitro by incubation of apo-ACP with CitX, CitG, ATP, and dephospho-CoA. ATP could not be substituted
with GTP, CTP, UTP, ADP, or AMP. In the absence of CitG or dephospho-CoA, AMP-ACP was formed.
Remarkably, it was not possible to further convert AMP-ACP to holo-ACP by subsequent incubation
with CitG and dephospho-CoA. This demonstrates that AMP-ACP is not an intermediate during the
conversion of apo- into holo-ACP, but results from a side activity of CitX that becomes effective in the
absence of its natural substrate. Our results indicate that holo-ACP formation proceeds as follows. First,
a prosthetic group precursor [presumably 2′-(5′′-triphosphoribosyl)-3′-dephospho-CoA] is formed from
ATP and dephospho-CoA in a reaction catalyzed by CitG. Second, holo-ACP is formed from apo-ACP
and the prosthetic group precursor in a reaction catalyzed by CitX.
Citrate lyase (EC 4.1.3.6) catalyzes the Mg2+-dependent
cleavage of citrate to acetate and oxaloacetate (Figure 1A).
This reaction represents the initial step of all known bacterial
citrate fermentation pathways (1-4). Citrate lyase has been
isolated from numerous bacterial species, while the bio-
chemical characterization was performed mainly with the
enzyme from Klebsiella pneumoniae (formerly Klebsiella
aerogenes). It is a complex of 550 kDa, formed by six copies
of each of the three different subunits [R (55 kDa), â (32
kDa), and ç (11 kDa)] (5, 6). The catalytic activity resides
on the R- and â-subunits, whereas the ç-subunit serves as
an acyl carrier protein (ACP)1 (7) containing 2′-(5′′-phos-
phoribosyl)-3′-dephospho-CoA as a prosthetic group (Figure
1B). This group is attached by its ribose 5′-phosphate moiety
via a phosphodiester linkage to serine-14 of the ACP (8-
12). As a prerequisite for catalytic activity, the thiol group
of the enzyme-bound CoA derivative needs to be acetylated,
resulting in the formation of an acetyl thioester (7, 13). This
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FIGURE 1: (A) Function of the different subunits in the reaction
catalyzed by citrate lyase and activation of the enzyme by citrate
lyase ligase. HS-R represents the prosthetic group. (B) Structure
of the 2′-(5′′-phosphoribosyl)-3′-dephospho-CoA prosthetic group
of citrate lyase.
9438 Biochemistry 2000, 39, 9438-9450
10.1021/bi000401r CCC: $19.00 © 2000 American Chemical Society
Published on Web 07/08/2000
reaction is catalyzed by citrate lyase ligase (EC 6.2.1.22) in
the presence of acetate and ATP (14). In the continuous turn-
over of the acetyl thioester during catalysis (13), the R-sub-
unit (acetyl-ACP:citrate ACP-transferase, EC 2.8.3.10) cata-
lyzes the exchange of the acetyl group with a citryl group,
forming acetate and citryl-ACP as products (15). The â-sub-
unit (citryl-ACP oxaloacetate-lyase, EC 4.1.3.34) in turn
catalyzes the Mg2+-dependent regeneration of acetyl-ACP
through the release of oxaloacetate from citryl-ACP (15).
ACPs carrying 2′-(5′′-phosphoribosyl)-3′-dephospho-CoA
as a prosthetic group have also been identified in citramalate
lyase (EC 4.1.3.22) from Clostridium tetanomorphum (16),
as well as in malonate decarboxylase (EC 4.1.1) from
Malonomonas rubra (17), K. pneumoniae (18), and Acine-
tobacter calcoaceticus (19). The biosynthetic pathway of this
prosthetic group has not yet been elucidated. A hypothetical
mechanism was proposed suggesting that apo-ACP sequen-
tially reacts with NAD+ and dephospho-CoA to form holo-
ACP (12).
Genetic analysis of K. pneumoniae citrate lyase led to the
identification of the citCDEFG gene cluster encoding citrate
lyase ligase (CitC), the ç-subunit (CitD), the â-subunit (CitE),
and the R-subunit (CitF) of citrate lyase, and a protein of
unknown function (CitG) which was postulated to be
involved in the biosynthesis of the prosthetic group (20).
The citC operon is induced under anoxic conditions in the
presence of citrate and Na+ ions, and its expression is strictly
dependent on the CitA/CitB two-component regulatory
system (21-23). Expression of the plasmid-encoded K.
pneumoniae citCDEFG genes in Escherichia coli resulted
in the formation of an inactive citrate lyase (20). However,
this inactive enzyme acquired catalytic activity in the
presence of acetyl coenzyme A, which is known to substitute
for the acetyl thioester of the native 2′-(5′′-phosphoribosyl)-
3′-dephospho-CoA prosthetic group (24). This and other
experiments showed that the inactivity of K. pneumoniae
citrate lyase synthesized in E. coli was due to the lack of
the entire prosthetic group or at least of the dephospho-CoA
moiety (20). Consequently, we proposed that holo-citrate
lyase formation requires one or more additional enzymes,
whose genes are not located in the immediate vicinity of
the citCDEFG cluster on the K. pneumoniae chromosome.
With the completion of the E. coli genome sequence (25),
a gene cluster that is very similar to the citCDEFG operon
of K. pneumoniae was identified in the region between 13.9
and 14.0 min. Most interestingly, the E. coli cluster contained
an additional gene, named citX, which was located between
citF and citG (Figure 2) and encoded a 20 kDa protein (26).
In this work, we show that the conversion of the apo-ACP
of citrate lyase into holo-ACP is dependent on CitG and
CitX, and we present evidence for the function of the two
proteins.
MATERIALS AND METHODS
CultiVation of E. coli. E. coli was routinely grown in Luria-
Bertani (LB) medium at 37 °C (27). Antibiotics were added
to the following final concentrations (micrograms per mil-
liliter): ampicillin (200), chloramphenicol (40), and kana-
mycin (50). E. coli DH5R (Bethesda Research Laboratories)
was used as the host for all cloning procedures. E. coli BL21-
(DE3) containing the phage T7 polymerase gene under the
control of a lacUV5 promoter (28) served as a host for
expression of target genes from pT7-7 and pET derivatives.
Expression cultures were prepared as follows. After cen-
trifugation (3000g for 8 min) of a 40 mL preculture grown
overnight at 37 °C, the cells were resuspended in 20 mL of
fresh LB medium. The cell suspension was subsequently used
to inoculate 2 L of the same medium containing appropriate
antibiotics, and the culture was incubated at 37 °C and 180
rpm. When the OD600 had reached a value between 0.5 and
0.8, the expression of the target genes was induced by adding
IPTG to a final concentration of 1 mM and the culture was
incubated for an additional 3 h at 37 °C and 180 rpm.
Subsequently, the cells were harvested by centrifugation (30
min at 3000g), washed once with 20 mL of 50 mM potassium
phosphate buffer (pH 7.0) containing 1 mM MgCl2, and
stored at -20 °C.
Plasmids. Plasmids and oligonucleotides used in this work
are listed in Tables 1 and 2, respectively. For the amplifica-
tion of E. coli genes by PCR, chromosomal DNA of strain
JM83 (29) or of strain CM2080 (30) was used as a template
and the reaction was performed with Pfu DNA polymerase
according to the instructions of the supplier Stratagene.
Vectors pET124b and pET224b constructed in this work
are derivatives of pET24b (Novagen) carrying the p15A
origin of replication derived from pACYC184 (31). This
confers compatibility of the pET124b and pET224b deriva-
tives with expression plasmids containing the ColE1 origin
of replication. To obtain pET124b, the 1.19 kb BssSI-FspI
fragment of pET24b was replaced by a 1.0 kb PVuII-HindIII
fragment from pACYC184. Prior to ligation, the 5′-overhangs
were made blunt-ended by a fill-in reaction with Klenow
polymerase. The pET224b vector was obtained by exchang-
ing the 1.19 kb BssSI-FspI fragment of pET24b against a
0.9 kb PVuII-SspI fragment from pACYC184. Again, the
5′-overhangs were made blunt-ended with Klenow poly-
merase. A noteworthy difference between pET224b and
pET124b is the presence of a second XbaI restriction site in
the latter plasmid.
FIGURE 2: Citrate lyase gene clusters of K. pneumoniae (K.p.), E.
coli (E.c.), H. influenzae (H.i.), and L. mesenteroides (L.m.). Gene
sequences homologous to E. coli citX are colored light gray.
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For the construction of an expression plasmid allowing
the production of proteins with a Strep-tag II anchor (32), a
linker encoding the Strep-tag II peptide WSHPQFEK was
cloned into vector pET224b cut with XhoI and HindIII. This
linker, which also contained an SpeI restriction site im-
mediately upstream of the Strep-tag II coding sequence, was
prepared by annealing the oligonucleotide strep-for with the
complementary oligonucleotide strep-rev, which resulted in
the formation of a HindIII- and an XhoI-compatible overhang.
Prior to ligation, the linker was phosphorylated with poly-
nucleotide kinase. The resulting construct was designated
pET224-Streptag.
For the construction of an expression plasmid containing
the E. coli citCDEFXG gene cluster, a 6.9 kb fragment was
amplified by PCR using the oligonucleotides eccl-for and
ec-citT-rev and the Expand High Fidelity PCR system from
Roche Diagnostics. For cloning purposes, the eccl-for pri-
mer contained an XbaI restriction site. The PCR product,
which also included the citT gene (26), was digested with
XbaI and XhoI, and the resulting 5.5 kb fragment was
cloned into pET24b cut with the same enzymes, resulting in
plasmid pET24-ECCL. The PCR-derived insert starts 55
bp upstream of the citC start codon and ends 203 bp
downstream of the citG stop codon within the citT coding
sequence.
For the construction of pET124-citX, the coding region
of the E. coli citX gene was amplified by PCR using the
primers ec-citX-for and ec-citX-rev. With this procedure, the
start codon became part of an NdeI restriction site while an
XhoI site was introduced immediately after the stop codon.
After digestion of the PCR product with NdeI and XhoI, the
555 bp DNA fragment was cloned into vector pET124b to
yield pET124-citX. To construct plasmid pET224-citXstrep,
the citX gene was amplified using the oligonucleotides ec-
citX-for and ec-citXstrep-rev. Thereby, the citX stop codon
was replaced with a SpeI restriction site. After digestion of
the PCR product with NdeI and SpeI, the 555 bp DNA
fragment was cloned into pET224-Streptag cut with the same
enzymes. This led to a plasmid encoding CitX with a
C-terminally attached Strep-tag II anchor.
To construct the expression plasmid pET22-citDhis, the
coding region of the E. coli citD gene was amplified using
primers ec-citD-for and ec-citDhis-rev that introduced an
NdeI restriction site at the start codon and replaced the stop
codon with an XhoI restriction site, respectively. After
digestion with NdeI and XhoI, the 315 bp PCR product was
cloned into pET22b cut with the same enzymes. Plasmid
pET22-citDhis encodes an ACP with a C-terminally attached
His tag.
For the construction of pET24-citGhis, the coding region
of the E. coli citG gene was amplified by PCR using the
primers ec-citG-for and ec-citGhis-rev. In this way, the start
codon became part of an NdeI restriction site and the stop
codon was replaced with an XhoI restriction site. After
digestion with NdeI and XhoI, the 876 bp PCR product was
cloned into vector pET24b restricted with the same enzymes.
The resulting plasmid pET24-citGhis encodes a CitG protein
with a C-terminally attached His tag. To construct plasmid
pET224-citGstrep, the citG gene was amplified using primers
ec-citG-for and ec-citGstrep-rev. In this way, the start codon
became part of an NdeI restriction site and the stop codon
was replaced with an SpeI site. After digestion with NdeI
and SpeI, the 876 bp PCR product was cloned into plasmid
pET224-Streptag cut with the same enzymes. This led to a
Table 1: Plasmids Used in This Work
plasmid relevant characteristics source/reference
pET22b AmpR; lacI+; expression vector for the production of proteins with a polyhistidine tag Novagen
pET24b KmR; lacI+; expression vector for the production of proteins with a polyhistidine tag Novagen
pET124b KmR; lacI+; pET24b derivative with the origin of replication from pACYC184 this work
pET224b KmR; lacI+; pET24b derivative with the origin of replication from pACYC184 this work
pET224-Streptag KmR; lacI+; pET24b derivative for the production of proteins with a Strep-tag II tag this work
pACYC184 CmR; TcR; origin of p15A 31
pET24-ECCL KmR; lacI+; citCDEFXG from E. coli in pET24b this work
pET124-citX KmR; lacI+; citX from E. coli in pET124b this work
pET224-citXstrep KmR; lacI+; citX from E. coli in pET224b-Streptag this work
pET22-citDhis ApR; lacI+; citD from E. coli in pET22b this work
pET24-citGhis KmR; lacI+; citG from E. coli in pET24b this work
pET24-citGstrep KmR; lacI+; citG from E. coli in pET224b-Streptag this work
pT7-CL ApR; citCDEFG from K. pneumoniae in pT7-7 20
pT7-CL¢G ApR; citCDEF from K. pneumoniae in pT7-7 20
Table 2: Oligonucleotides Used in This Worka
oligonucleotide sequence
eccl-for 5′-CCCTCTAGAGAACAACATTCGTTGCAAATCGATAAC-3′
ec-citT-rev 5′-CCGCGAATTCTTAGTTCCACATGGCGAGAATCGGCCAG-3′
ec-citX-for 5′-AAATTTCATATGCACCTGCTTCCTGAACTCGCC-3′
ec-citX-rev 5′-GGGCCCCTCGAGTTAGTTGACGTTGCAGGCATCGAC-3′
ec-citXstrep-rev 5′-GGGCCCACTAGTGTTGACGTTGCAGGCATCGACATC-3′
ec-citD-for 5′-TATTATCATATGAAAATAAACCAGCCCGCCGTTGC-3′
ec-citDhis-rev 5′-CGCCGCCTCGAGTTGGCAATCCTCCCATGGCAGAGC-3′
ec-citG-for 5′-TATTATCATATGTCGATGCCTGCAACGTCAACT-3′
ec-citGhis-rev 5′-GGGCCCCTCGAGAATCTGTGCTAAAAACCAGGTAAG-3′
ec-citGstrep-rev 5′-GGGCCCACTAGTAATCTGTGCTAAAAACCAGGTAAG-3′
strep-for 5′-AGCTTACTAGTTGGAGCCACCCGCAGTTCGAAAAATAAC-3′
strep-rev 5′-TCGAGTTATTTTTCGAACTGCGGGTGGCTCCAACTAGTA-3′
a Restriction sites introduced by the oligonucleotides are underlined.
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plasmid encoding CitG with a C-terminally attached Strep-
tag II anchor.
The correctness of the PCR-derived parts of all the
plasmids described above except pET24-ECCL was verified
by DNA sequencing.
SelectiVe Labeling of Plasmid-Encoded Proteins with [35S]-
Methionine. The selective [35S]methionine labeling of pro-
teins whose genes are under the control of a T7 promoter
was performed essentially as described previously (33).
Preparation of Cell Extracts and Protein Determination.
For the preparation of cell extracts, 1 g of cells (wet weight)
obtained from the expression cultures was resuspended in 4
mL of a suitable buffer precooled on ice. For the determi-
nation of citrate lyase activity, 50 mM potassium phosphate
buffer (pH 7.0) containing 1 mM MgCl2 was used. For the
purification of His-tagged proteins, buffer TNI5 (see below)
was employed and for the purification of Strep-tagII-tagged
proteins buffer W (see below). After addition of a protease
inhibitor cocktail (Complete Mini-EDTA free, Roche Diag-
nostics) and DNase I (0.25 mg/mL), the cells were disrupted
by three passages through a French pressure cell at 108 MPa.
Intact cells and cell debris were removed by centrifugation
(30 min at 27 000g). The cell-free supernatant was subjected
to ultracentrifugation (1 h at 150 000g) to sediment the
membrane fraction. The resulting supernatant (“cell extract”)
was immediately used for enzymatic studies or protein
purification. Protein concentrations were determined with the
bicinchoninic acid (BCA) protein assay (34) using ovalbumin
as the standard.
Citrate Lyase Assay. Citrate lyase activity was determined
at 25 °C in a coupled spectrophotometric assay with malate
dehydrogenase essentially as described previously (20),
except that only 30 units instead of 60 units of malate
dehydrogenase (Roche Diagnostics) was used per assay. To
convert inactive desacetyl citrate lyase to the active acetyl
form, the cell extracts, which contained citrate lyase ligase
(citC gene product), were incubated for 30 min at 37 °C
with 20 mM acetate and 2.7 mM ATP before they were
tested in the citrate lyase assay.
Purification of ACPHis and X-ACPHis. E. coli BL21(DE3)
containing pET22-citDhis either alone or together with
pET124-citX was cultured, and cell extracts were prepared
using buffer TNI5 (the number indicates the imidazole
concentration in millimolar), which contained 20 mM Tris,
500 mM NaCl, and 5 mM imidazole. The pH of all TNI
buffers was adjusted to 7.9 by addition of HCl. Cell extracts
were passed through a 0.2 ím filter before being loaded onto
columns containing His-bind resin in a bed volume of 2 mL
(Novagen) equilibrated with buffer TNI5. The columns were
washed with 15 mL of buffer TNI5, 15 mL of TNI30, and
10 mL of TNI60. Apo-ACPHis or X-ACPHis was eluted with
10 mL of buffer TNI100 in fractions of 1 mL. The protein-
containing fractions were pooled and stored at 4 °C.
Purification of CitGHis. E. coli BL21(DE3) containing
pET24-citGhis was cultured, and cell extracts were prepared.
All TNI buffers used in the purification of CitGHis contained
8% (v/v) glycerol for prevention of precipitation of the
protein. Purification of CitGHis was performed by Ni2+-
chelate affinity chromatography as described for ACPHis,
except that the column was washed with 15 mL each of
buffer TNI5, TNI15, and TNI30 followed by 10 mL of buffer
TNI60. Subsequently, CitGHis was eluted with 10 mL of
buffer TNI100 in fractions of 1 mL. The protein-containing
fractions were pooled and stored at 4 °C.
Purification of CitXStrep and CitGStrep. E. coli BL21(DE3)
harboring pET224-citXstrep or pET224-citGstrep was cul-
tured, and a cell extract was prepared using buffer W, which
consisted of 100 mM Tris-HCl (pH 8.0) and 1 mM EDTA.
The cell extract was passed through a 0.2 ím filter and then
loaded onto a column containing StrepTactin sepharose in a
bed volume of 2 mL (IBA, Go¨ttingen, Germany) equilibrated
with 10 mL of buffer W (35). The column was washed with
10 mL of buffer W, and CitXStrep or CitGStrep was eluted with
10 mL of buffer E (buffer W containing 2.5 mM desthio-
biotin) in 0.5 mL fractions. The protein-containing fractions
were pooled and stored at 4 °C.
Mass Spectrometric Analysis of the Different-Sized Forms
of ACP. To determine the mass of the compound attached
to ACP by CitX, purified apo-ACPHis and X-ACPHis were
added to separate lanes of a 15% SDS-polyacrylamide gel
(36). After electrophoresis, the gel was stained with GelCode
Blue Stain Reagent (Pierce) until the proteins became visible.
The bands were excised, and the gel slices were washed twice
for 3 min in 100 mM ammonium bicarbonate, cut into
smaller pieces, and dried in a vacuum speed evaporator. The
dried gel fragments were rehydrated with 20 íL of 100 mM
ammonium bicarbonate containing 0.1 íg of sequencing
grade trypsin (Promega). Digestion in the gel was carried
out overnight at room temperature. Peptides were extracted
with 50 íL of 100 mM ammonium bicarbonate followed by
two extraction steps with 50 íL of an acetonitrile/formic acid
(50%/5%) mixture in water. The combined extracts were
reduced to a volume of 10 íL in a vacuum speed evaporator.
The masses of the tryptic peptides were determined by
MALDI-TOF mass spectrometry (P. James, Protein Chem-
istry Facility, ETH Zu¨rich, Switzerland). Approximately 1
pmol in 0.5 íL was added to the same volume of a saturated
matrix solution (R-cyano-4-hydroxycinnamic acid in a 50%
acetonitrile/1.25% trifluoroacetic acid mixture) and allowed
to dry at ambient temperature. Spectra (positive ion mode)
were recorded with a Voyager Elite MALDI-TOF mass
spectrometer (Perseptive Biosystems, Framingham, MA) in
the delayed extraction and reflector mode using an accelerat-
ing voltage of 20 kV, a pulse delay time of 150 ns, a grid
voltage of 60%, and a guide wire voltage of 0.05%. Spectra
were averaged from 32 scans. Calibration was external to
the samples.
For the determination of intact proteins (apo-ACPHis and
holo-ACPHis), samples were analyzed in the delayed extrac-
tion linear mode using an accelerating voltage of 25 kV, a
pulse delay time of 150 ns, a grid voltage of 91%, and a
guide wire voltage of 0.1%. Spectra were averaged from 32
scans.
Tandem Mass Spectrometry of the Serine-14-Containing
Tryptic Peptide of ACP. The unfractionated peptide mixture
obtained after tryptic in-gel digestion of apo-ACPHis and
X-ACPHis (as described above) was infused at a rate of 0.1
íL/min into a Finnigan LCQ (San Jose, CA) ion trap mass
spectrometer. The electrospray source was modified to
accommodate low flow rates by employing a gold-coated
15 ím inside diameter spraying tip (New Objective, Inc.,
Cambridge, MA). Parent peptide ion isolation was performed
with a mass window of 3.0 amu. Peptide fragmentation was
achieved by resonance excitation with a relative energy of
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35%. MS/MS spectra were averaged from 10 scans in the
centroid mode employing software provided by the manu-
facturer.
CleaVage of Compound X (AMP) and of the Prosthetic
Group from ACP. In vivo synthesized X-ACPHis, in vitro
synthesized putative holo-ACPHis, or purified E. coli citrate
lyase was incubated for 30 min at 65 °C in the presence of
0.1 M NaOH (8). After the pH of the solution had been
adjusted to about 5 with HCl, the precipitated protein was
removed by centrifugation. The compounds that had been
cleaved off by the alkaline treatment were present in the
supernatant which was used for further analysis by reversed
phase HPLC.
ReVersed Phase Chromatography of Compound X (AMP)
and of the Prosthetic Group. The HPLC analysis of
compound X and of the prosthetic group obtained by alkaline
treatment was performed essentially as described previously
(17). A Hypersil ODS column (250 mm  4 mm, 5 ím
particle size, Hewlett-Packard) was equilibrated with buffer
B [0.2 M potassium phosphate (pH 5.0)] at a flow rate of 1
mL/min. Elution was performed with a linear gradient (0 to
60% within 18 min) of buffer C [0.2 M potassium phosphate
(pH 5.0) containing 20% (v/v) acetonitrile] with UV detection
at 254 nm. The peak fractions were collected and stored at
-20 °C for further analyses. The fraction containing com-
pound X was evaporated to dryness, redissolved in H2O, and
used for an enzymatic AMP assay.
AMP Assay. AMP was quantified in a coupled enzymatic
assay with myokinase, pyruvate kinase, and lactate dehy-
drogenase (37). The assay mixture contained, in a final
volume of 200 íL, 100 mM HEPES (pH 7.5), 5 mM MgCl2,
50 íM NADH, 5 mM PEP, 100 íM ATP, 7 units of myo-
kinase, 20 units of pyruvate kinase, and 55 units of lactate
dehydrogenase (enzymes from Roche Diagnostics GmbH).
The reaction was started by adding different amounts of AMP
or compound X obtained after alkaline treatment of X-ACPHis
and subsequent reversed phase chromatography. The AMP-
dependent oxidation of NADH was assessed in a spectro-
photometer at 340 nm ( ) 6.3 mM-1 cm-1).
RESULTS
Identification of the Genes Required for the Biosynthesis
of the Prosthetic Group of Citrate Lyase. The E. coli citrate
lyase gene cluster (citCDEFXG) differs from that of K.
pneumoniae (citCDEFG) by the presence of an additional
gene that we designated citX (26). A database search revealed
that genes homologous to citX are also present in the citrate
lyase gene clusters of Haemophilus influenzae (38), Leu-
conostoc mesenteroides (39), and Leuconostoc (Weissella)
paramesenteroides (40). In these species, however, they are
not separate genes, but are fused to the citG homologues
downstream (Figure 2). Thus, citX is present in all known
citrate lyase gene clusters except the one of K. pneumoniae.
Since the K. pneumoniae citCDEFG genes are not sufficient
for the formation of holo-citrate lyase (20), we hypothesized
that citX could be the gene missing in the K. pneumoniae
cluster. In a first attempt to verify this assumption, we tested
whether expression of the E. coli citCDEFXG genes results
in the formation of an active citrate lyase. For this purpose,
the genes were amplified by PCR and cloned into expression
vector pET24b, resulting in pET24-ECCL. This plasmid was
introduced into E. coli BL21(DE3), and expression of the
target genes was induced by IPTG. Extracts prepared from
these cells possessed high citrate lyase activity (4.5 units/
mg of protein), whereas extracts from control cells containing
pET24b contained negligible activity (<0.01 unit/mg of
protein). This shows that the plasmid-encoded citCDEFXG
genes are sufficient for the production of an active citrate
lyase and that the chromosomally encoded citCDEFXG genes
are not expressed during aerobic growth in rich medium, as
expected.
We then tested whether the E. coli citX gene can
complement the K. pneumoniae citCDEFG genes with
respect to the formation of an active citrate lyase. Indeed,
IPTG-induced coexpression of the corresponding genes in
E. coli BL21(DE3) transformed with pET124-citX and pT7-
CL (20) resulted in citrate lyase activity of up to 8.2 units/
mg of protein in the cell-free extract. This provided
conclusive evidence that citX is indeed the missing gene in
the K. pneumoniae gene cluster.
The citG gene is present within all citrate lyase gene clus-
ters known hitherto (Figure 2), indicating that it is involved
in the biosynthesis of the prosthetic group. Since we now
had a suitable assay system, we tested the role of citG in
the formation of an active citrate lyase. E. coli BL21(DE3)
was transformed with pET124-citX and pT7-CL¢G, a deriv-
ative of pT7-CL lacking the citG gene (20), and target gene
expression was induced by IPTG. Cell-free extracts prepared
from these cells did not possess citrate lyase activity (e0.01
unit/mg of protein), showing for the first time that CitG is
essential for the formation of a functional citrate lyase.
From the results described above, it is evident that
citCDEFG and citX represent the minimal set of genes
required for the formation of a functional citrate lyase.
Nevertheless, the exact function of CitX and CitG still
remained to be elucidated. As discussed previously (20), the
conversion of apo-ACP into holo-ACP involves at least two
steps, i.e., the formation of the phosphodiester bond between
the hydroxyl group of a serine residue and the prosthetic
group and the formation of the R-1,2-glycosidic linkage be-
tween the 5′-phosphoribosyl precursor and dephospho-CoA.
It thus appeared possible that one of these reactions is cata-
lyzed by CitX and the other by CitG. To obtain hints about
the function of the two proteins, the size of the ACP was
examined in the absence and in the presence of CitG and/or
CitX. For this purpose, E. coli BL21(DE3) was transformed
with pET124-citX in combination with either pT7-CL or
pT7-CL¢G, or with each of the three plasmids separately.
The plasmid-encoded proteins, whose genes are transcribed
by the T7 RNA polymerase, were selectively labeled with
[35S]methionine in vivo. Whole-cell lysates were analyzed
by SDS-PAGE followed by autoradiography (Figure 3). The
apparent absence of the CitC protein (38.5 kDa) in the
autoradiogram is caused by the lower expression level of
the citC gene, as shown previously (20). Besides CitE (31.4
kDa), CitF (54.7 kDa), CitG (32.6 kDa), and CitX (20.3
kDa), three different-sized forms of the ACP (CitD, calcu-
lated mass of 10.4 kDa) were detected in this experiment,
i.e., the apo form (apparent mass of 12.0 kDa), the holo form
(apparent mass of 14.5 kDa), and an intermediate-sized form
(14.0 kDa) which was designated X-ACP. In the absence of
CitX, only the apo form could be detected (Figure 3, lanes
3 and 4). The intermediate-sized form was synthesized in
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the presence of CitX and the absence of CitG (Figure 3, lane
2). The formation of the holo form finally was dependent
on the presence of both CitX and CitG (Figure 3, lane 1).
These results indicate that CitX is responsible for the
attachment of the prosthetic group to apo-ACP, whereas CitG
presumably catalyzes the formation of the glycosidic linkage
between dephospho-CoA and the phosphoribosyl moiety.
Identification of X-ACP as AMP-ACP. The studies reported
above gave us the opportunity to selectively synthesize
X-ACP. The identification of X might give clues about the
precursor of the phosphoribosyl moiety, which was still
unknown. To simplify our system, we presumed that the
conversion of apo-ACP into holo-ACP is independent of the
two other subunits of citrate lyase. Moreover, to facilitate
the purification of the different ACP forms, we constructed
the expression plasmid pET22-citDhis encoding a His-tagged
derivative of the E. coli ACP. The recombinant ACPHis
protein (106 amino acid residues, 11.8 kDa) contained eight
additional residues (LEHHHHHH) at its C-terminus, allow-
ing purification by Ni2+-chelate affinity chromatography.
For the synthesis of apo-ACPHis and X-ACPHis, pET22-
citDhis was introduced into E. coli BL21(DE3) together with
pET124b and pET124-citX, respectively. SDS-PAGE analy-
sis of the ACPs purified from the two strains confirmed that
the one synthesized in the presence of CitX had a larger
apparent mass than the one synthesized in its absence (data
not shown). We assumed that the covalent modification of
ACP catalyzed by CitX would occur at serine-14, since this
residue was previously shown to carry the prosthetic group
of the K. pneumoniae citrate lyase (11). N-Terminal protein
sequencing supported this assumption. In the case of apo-
ACPHis, the sequence XKINQPAVAGTLESGD was ob-
tained, in agreement with the DNA-derived sequence,
whereas X-ACPHis yielded the same sequence except that
the serine residue at position 14 could not be identified,
presumably because of its modification. To obtain the mass
difference between apo-ACPHis and X-ACPHis, the proteins
were in-gel digested with trypsin and the resulting peptides
were analyzed by MALDI-TOF mass spectrometry. As
shown in Figure 4A, three dominant peaks above 1000 Da
were detected for apo-ACP, with masses of 1001.67,
1871.01, and 2099.1 Da. They correspond to tryptic peptides
of apo-ACP extending from position 47 to 55 (TTILDVLAR,
predicted mass of 1001.60 Da), from position 3 to 20
(INQPAVAGTLESGDVMIR, predicted mass of 1870.97
Da), and from position 21 to 39 (IAPLDTQDIDLQINSS-
VEK, predicted mass of 2099.09 Da). In the mass spectrum
obtained for X-ACPHis (Figure 4B), the 1871.01 Da peptide
was replaced by a 2200.14 Da peptide, resulting in a mass
difference of 329.13 Da. In addition, a mass of 1873.7 Da
was detected, which presumably represents a metastable
fragment due to the broad and unresolved isotope peaks
observed for this peptide compared to the others in this
spectrum. To confirm that the 2200 Da peptide is a derivative
of the 1871 Da peptide, both were further analyzed by
tandem mass spectrometry. Fragments that do not contain
the serine residue (e.g., b1-b11 and y1-y6) were expected
to have identical masses in both peptides, whereas those
fragments including the serine residue (e.g., b12-b17 and y7-
y17) should differ by 329 Da. As shown in Table 3, fragments
b6, b7, b14, y3, y4, y11, and y12 corresponded with our
expectations and thus confirmed that the 2200 Da peptide is
a derivative of the 1871 Da peptide. Whereas in the case of
the 1871 Da peptide 26 of the 32 major fragments cor-
responded to predicted masses [calculated with the software
MS-Product of the University of California at San Francisco
Mass Spectrometry Facility (http://donatello.ucsf.edu)], only
15 of the 33 major fragments corresponded in the case of
the 2200 Da peptide. The unassigned fragments presumably
represent serine-containing peptides in which the attached
group (AMP, see below) was no longer intact but partially
deleted by fragmentation.
FIGURE 3: Detection of the three different-sized forms of the K.
pneumoniae ACP. After selective [35S]methionine labeling of
proteins whose genes are transcribed by T7 RNA polymerase, the
E. coli BL21(DE3) cells were harvested by centrifugation. Proteins
were separated by SDS-PAGE followed by autoradiography (33).
The cells harbored the following plasmids: lane 1, pT7-CL and
pET124-citX; lane 2, pT7-CL¢G and pET124-citX; lane 3, pT7-
CL; lane 4, pT7-CL¢G; and lane 5, pET124-citX.
FIGURE 4: MALDI-TOF mass spectra of peptides obtained from
apo-ACPHis (A) and X-ACPHis (B) after in-gel trypsin digestion.
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UV-vis spectra of apo-ACPHis revealed an absorption
maximum at 280 nm, whereas that of X-ACPHis had been
shifted to 264 nm (data not shown). This shift, which
indicated that a nucleotide had been attached to ACP, and
the mass difference of 329.13 Da led us to the assumption
that adenosine monophosphate (AMP) represents the com-
pound attached to serine-14 of X-ACP. To verify our
assumption, compound X attached to ACPHis by CitX was
cleaved off by alkaline treatment and subsequently analyzed
by reversed phase HPLC (Figure 5). The elution profile
revealed one major peak with a retention time of 7.4 min.
When X and commercially available 5′-AMP at concentra-
tions of 0.1 mM were cochromatographed, AMP coeluted
with the peak at 7.4 min, providing convincing evidence that
the majority of compound X is identical with AMP. The 7.4
min HPLC fraction had the same UV absorption spectrum
as 5′-AMP with a maximum at 259 nm (not shown). After
evaporation to dryness and dissolution in H2O, the compound
was tested in a coupled enzymatic AMP assay with myo-
kinase, pyruvate kinase, and lactate dehydrogenase (37).
Myokinase is absolutely specific for adenosine phosphates
and does not react with other nucleoside phosphates. Addition
of different amounts of X to the assay mixture resulted in
NADH oxidation, and the AMP concentration measured by
this assay agreed roughly with the one calculated from the
absorption at 260 nm using an extinction coefficient of 15.0
mM-1 cm-1. These results provide additional support for the
identity of compound X with 5′-AMP.
In Vitro ConVersion of Apo-ACP into AMP-ACP Using
Purified CitX. The identification of X-ACP as adenylylated
ACP suggested that ATP is the donor of the adenylyl group
and that CitX possesses adenylyltransferase activity. To
verify these assumptions, we established an in vitro system
for the conversion of apo-ACPHis into AMP-ACPHis with
purified proteins. For this purpose, the expression plasmid
pET224-citXstrep was constructed, encoding a CitX deriva-
tive with the Strep-tag II peptide (32). CitXStrep (193 amino
acid residues, 21.5 kDa) contained 10 additional residues
(TSWSHPQFEK) at the C-terminus, which allowed purifica-
tion by StrepTactin affinity chromatography (35). For the
in vitro assay, apo-ACPHis (19 íM) and CitXStrep (5 íM) were
mixed in either the presence or absence of 6 mM ATP. At
different times after the start of the reaction, samples were
taken and analyzed by SDS-PAGE (Figure 6). In the
samples containing ATP, the conversion of apo-ACPHis into
a slightly larger form could be observed, which was
completed after 5 min under our reaction conditions. In the
samples without ATP, no conversion of the apo-ACPHis was
Table 3: Fragments Obtained by Tandem Mass Spectrometry of the
1871 Da Tryptic Peptide from Apo-CitD
(INQPAVAGTLESGDVMIR) and of the 2200 Da Tryptic Peptide
from CitX-Modified CitDa
measured mass calculated mass assignment
1871 Da peptide
356.2 356.2 b3
379.3 379.2 QPAV-NH3
394.1 394.2 NQPA-NH3
419.5 419.2 y3
493.3 493.2 NQPAV-NH3
518.4 518.3 y4
606.3 606.3 b6-NH3
623.4 623.4 b6
694.5 694.4 b7
834.5 834.5 b9-H2O
906.6 906.4 y8
965.5 965.5 b10
1019.6 1019.5 y9
1094.5 1094.6 b11
1120.5 1120.6 y10
1177.6 1177.6 y11
1248.7 1248.6 y12
1329.9 1329.7 y13-H2O
1347.7 1347.7 y13
1353.7 1353.7 b14
1435.8 1435.7 b15-NH3
1452.7 1452.7 b15
1515.9 1515.8 y15
1583.7 1583.8 b16
1696.7 1696.9 b17
2200 Da peptide
419.4 419.2 y3
518.5 518.3 y4
623.4 623.4 b6
694.5 694.4 b7
888.5 888.3 AGTLES*
927.5 927.3 AGTLES*G-H2O
1257.7 1257.5 TLES*GDVMI-H2O
1329.7 1329.5 AVAGTLES*GDV
1442.6 1442.5 AVAGTLES*GDVM-H2O
1506.7 1506.6 y11*
1577.7 1577.6 y12*
1682.6 1682.7 b14*
a Only those masses are shown which corresponded to predicted
fragments [calculated with the software MS-Product of the University
of California at San Francisco Mass Spectrometry Facility (http://
donatello.ucsf.edu)]. For the 2200 Da peptide, the masses were
calculated under the assumption that the serine residue is adenylylated
(see the text), resulting in a mass increase of 329 Da. The corresponding
fragments are indicated with an asterisk.
FIGURE 5: Coelution of AMP and the compound obtained after
alkaline treatment of X-ACPHis during reversed phase HPLC.
Purified X-ACPHis was treated with 0.1 M NaOH for 30 min at 65
°C to cleave off compound X. After pH adjustment to 5.0 with
HCl and removal of the precipitated protein by centrifugation, the
compound cleaved off was subjected to HPLC either without added
AMP (bottom) or together with commercially available AMP (top).
For detection, the UV absorption at 254 nm was measured.
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detected. To confirm the nature of the modification, the in
vitro produced putative AMP-ACPHis was in-gel digested
with trypsin and the resulting peptides were subjected to
MALDI-TOF mass spectrometry. The resulting chromato-
gram (not shown) revealed peptide masses that were identical
to those obtained with AMP-ACPHis synthesized in vivo. This
result showed that CitX alone is sufficient to catalyze the
ACP adenylyltransferase reaction.
To test the substrate specificity of CitX, ATP was replaced
with GTP, CTP, or UTP. Remarkably, apo-ACP was
converted to a larger-sized form with each of these nucleoside
triphosphates (rates in the following order, CTP > GTP and
UTP). Thus, CitX could use different nucleotides and
functioned as a nucleotidyltransferase. Since NAD+ had been
proposed as a possible precursor of the phosphoribosyl
moiety of the citrate lyase prosthetic group (12), we also
tested whether apo-ACP could be modified by CitX with
NAD+ as a substrate. No conversion of apo-ACP into a
larger-sized form was observed in this experiment.
In Vitro ConVersion of Apo-ACP into Holo-ACP with
Purified CitX and CitG. The experiments described above
indicated that the formation of AMP-ACP could be the first
step in the synthesis of holo-ACP. The second one then
would be the displacement of the adenine moiety by the
2-hydroxyl group of dephospho-CoA catalyzed by CitG.
However, it is also possible that in vivo first a precursor of
the prosthetic group is formed and then transferred to apo-
ACP by CitX. To distinguish between these possibilities, we
set up an in vitro system for the conversion of apo-ACPHis
into holo-ACPHis with purified components. For this purpose,
the plasmid pET24-citGhis was constructed encoding a His-
tagged derivative of the E. coli CitG protein. The recombi-
nant CitGHis (300 amino acids, 32.7 kDa) contained eight
additional amino acid residues at its C-terminus (LEHHH-
HHH) and was purified by Ni2+-chelate affinity chroma-
tography.
In a first set of experiments, apo-ACPHis (32 íM) was
incubated at room temperature with CitXStrep (8 íM),
CitGHis (4 íM), ATP (1 mM), and dephospho-CoA (1
mM). Aliquots were taken 0, 15, and 30 min after start of
the reaction with ATP and subjected to SDS-PAGE. As
shown in Figure 7 (lanes 2-4), the apparent size of the ACP
increased from about 12.5 kDa (apo form) to about 15.0 kDa.
Conversion was almost complete after 15 min, and an
intermediate-sized form was not detectable. When dephos-
pho-CoA was omitted from the assay, the apparent ACP size
increased from 12.5 to 14.5 kDa, which corresponds to AMP-
ACPHis (Figure 7, lanes 5-7). The minor protein band with
a size of 15 kDa visible in lanes 5-10 represents a
degradation product of CitXStrep rather than an ACP form.
When either ATP or CitXStrep was omitted from the assay,
no conversion of apo-ACPHis into a larger-sized form was
observed (Figure 7, lanes 8-13). When apo-ACPHis was
incubated with ATP, dephospho-CoA, and CitXStrep, but
without CitGHis, only AMP-ACPHis was formed (data not
shown). These results indicate that the ACP with an apparent
size of 15.0 kDa represents the holo form and that its forma-
tion is dependent on dephospho-CoA, ATP, CitX, and CitG.
In contrast to the previous experiments on the conversion
of apo-ACP by CitX alone, ATP could not be replaced by
GTP, CTP, or UTP in the formation of the putative holo-
ACP. Moreover, ATP could not be substituted by ADP or
AMP. These data indicate that ATP is the only precursor of
the phosphoribosyl moiety of the prosthetic group and that
both the adenine and the triphosphate moiety are essential
for holo-ACP formation.
To confirm that the in vitro formed ACP with an apparent
size of 15.0 kDa in fact represents the holo form, it was
in-gel digested with trypsin and the resulting peptides were
analyzed by MALDI-TOF mass spectrometry. We expected
that the 1871 Da peptide containing serine-14 was replaced
by a 2754 Da peptide, caused by the attachment of the 883
Da prosthetic group. Although the 1871 Da peptide was
indeed absent in the mass spectrum of the tryptically digested
15.0 kDa ACP, a peptide with a mass of 2754 Da was not
detectable (data not shown). We tried different protocols for
in-gel trypsin digestion, as well as trypsin digestion in
solution of either native or urea-denatured protein, but in no
case could a peptide of the expected size be identified by
MALDI-TOF mass spectrometry. Therefore, two alternative
approaches were used to verify the identity of the prosthetic
group of the in vitro formed 15.0 kDa ACP.
(i) The masses of undigested apo-ACPHis (12.5 kDa) and
of undigested putative holo-ACPHis (15.0 kDa) were deter-
mined by MALDI-TOF mass spectrometry in the linear
mode. To purify the different ACPHis forms from the assay
mixtures by Ni2+-chelate affinity chromatography, we
replaced CitGHis by a CitG protein tagged with a Strep-tag
II peptide. For this purpose, the expression plasmid pET224-
citGstrep was constructed. The recombinant CitGStrep protein
(302 amino acid residues, 32.9 kDa) contained 10 additional
residues (TSWSHPQFEK) at its C-terminus and was isolated
by StrepTactin affinity chromatography (35). The assay
mixture for in vitro conversion of apo- into holo-ACP
contained 50 íM apo-ACPHis, 2.5 íM CitXStrep, 4 íM
CitGStrep, 1 mM ATP, and 1 mM dephospho-CoA. In an
otherwise identical control reaction, ATP was omitted to
prevent the conversion of apo-ACPHis. After incubation for
90 min at room temperature, the different forms of ACPHis
were purified from the two reaction mixtures using Ni2+-
FIGURE 6: ATP-dependent in vitro conversion of apo-ACP into
AMP-ACP. Purified apo-ACPHis (19 íM) and CitXStrep (5 íM) were
incubated at room temperature in the absence (lanes 2 and 6) and
in the presence of 6 mM ATP (lanes 3-5). Aliquots were taken 0,
5, and 30 min after the start of the reaction with CitXStrep, mixed
with an equal volume SDS sample buffer, and subjected to SDS-
PAGE. The gel was subsequently stained with Coomassie brilliant
blue: lane 1, protein standard; lanes 2 and 3, 0 min; lane 4, 5 min;
and lanes 5 and 6, 30 min.
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NTA columns and subjected to mass spectrometry. As shown
in Figure 8, apo-ACPHis isolated from the control reaction
yielded a mass of 11 762.8 Da, which corresponds to the
1-fold protonated species (M + H)+ and deviates by 0.07%
from the calculated mass of 11 754.28 Da. In addition, a
mass of 5879.65 Da corresponding to the 2-fold protonated
species (M + 2H)2+ was present. The putative holo-ACPHis
sample yielded a dominant mass of 12 646.2 Da, but also
contained a minor amount of apo-ACPHis with a mass of
11 763.8 Da. Subtraction gives a mass difference of 883.3
Da, which corresponds exactly to the mass of the prosthetic
group. The mass of 6325.05 Da corresponds to the 2-fold
protonated holo-ACP, whereas the identity of the 8429.06
Da peak is unknown.
(ii) The prosthetic groups of an active E. coli citrate lyase
preparation and of the in vitro synthesized 15.0 kDa ACP
were compared by reversed phase HPLC. For that purpose,
E. coli citrate lyase containing a His-tagged ACP was
overproduced and isolated by Ni2+-chelate affinity chro-
matgraphy (K. Schneider et al., unpublished results). The
purified protein had citrate lyase activity (8 units/mg of
protein) and thus was present in the holo form, at least
partially. The prosthetic group was cleaved off from citrate
lyase and from the in vitro synthesized 15.0 kDa ACP by
alkaline treatment. As shown in Figure 9, reversed phase
HPLC of the two resulting samples yielded identical chro-
matograms with peaks eluting at 7.0 and 14.3 min. From
the chromatographic behavior of reference samples (adenine,
AMP, ADP, ATP, dephospho-CoA, and CoA), we con-
cluded that the peak eluting at 14.3 min represented the en-
tire prosthetic group, whereas the peak eluting at 7.0 min
presumably was a degradation product. The identity of
the peaks was confirmed by cochromatography (data not
shown). Taken together, the results of mass spectrometry
and HPLC analysis confirmed the assumption that the
prosthetic group formed in vitro was identical with the one
formed in vivo.
NonconVersion of AMP-ACP into Holo-ACP. The avail-
ability of the in vitro system for the conversion of apo- into
holo-ACP allowed us to test if AMP-ACP can be converted
to the holo form. For this purpose, apo-ACPHis (22 íM) was
incubated with CitXStrep (5 íM) and ATP (1 mM) for 30
min at room temperature. Subsequently, the assay mixture
was split, and one half was supplemented with CitGHis (4
íM) and dephospho-CoA (1 mM) and the other half with
CitGHis (4 íM) only. The mixtures were incubated for an
additional 30 min. At different times, samples were taken
and subjected to SDS-PAGE. As shown in Figure 10, apo-
ACPHis was completely converted to AMP-ACPHis after
incubation for 30 min with CitXStrep and ATP. However, no
conversion of AMP-ACPHis into holo-ACPHis was observed
after incubation with CitGHis and dephospho-CoA. This result
FIGURE 7: In vitro conversion of apo-ACP into holo-ACP. Apo-ACPHis (32 íM) was incubated at room temperature with CitGHis (4 íM),
CitXStrep (8 íM), ATP (1 mM), and dephospho-CoA (1 mM). Aliquots were taken 0, 15, and 30 min after the start of the reaction with
ATP and subjected to SDS-PAGE (lanes 2-4). Besides this complete assay mixture, three others were analyzed which lacked either
dephospho-CoA (lanes 5-7), ATP (lanes 8-10), or CitXStrep (lanes 11-13). Lanes 1 and 14 contained the protein standard. The gel was
stained with Coomassie brilliant blue.
FIGURE 8: MALDI-TOF mass spectra of apo-ACPHis (A) and the
in vitro synthesized holo-ACPHis (B).
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strongly implied that AMP-ACPHis is not an intermediate in
the synthesis of holo-ACP, but a byproduct formed by CitX
in the absence of its natural substrate. Therefore, holo-ACP
formation most likely proceeds via the initial formation of a
prosthetic group precursor from dephospho-CoA and ATP
by CitG. This precursor is subsequently transferred to apo-
ACP by CitX. According to the structure of the prosthetic
group and to the fact that ATP but not ADP or AMP served
as the substrate, the prosthetic group precursor presumably
is 2′-(5′′-triphosphoribosyl)-3′-dephospho-CoA.
DISCUSSION
Citrate lyase carries a 2′-(5′′-phosphoribosyl)-3′-dephos-
pho-CoA prosthetic group (Figure 1B). In this work, we have
identified the genes and the precursors required for the
biosynthesis of this prosthetic group, and we provide strong
evidence for the function of the enzymes involved. In a first
set of experiments, we showed that in E. coli the proteins
encoded by citX and citG are essential for the formation of
an active citrate lyase. If both genes were expressed together
with citCDEF, holo-ACP was formed and an active citrate
lyase was present in the cells. In the absence of CitX, only
the apo-ACP was formed, whereas in the absence of CitG,
an intermediate-sized X-ACP was synthesized (Figure 3).
X-ACP was identified as AMP-ACP, with AMP attached to
serine-14 of the ACP, i.e., to the same residue that carries
the prosthetic group. The latter result indicated that CitX
possesses ACP adenylyltransferase activity in vivo. This was
subsequently confirmed in vitro with purified CitX and apo-
ACP plus ATP as substrates. However, whereas in vivo only
ATP was used as a substrate by CitX, in vitro CTP, GTP,
and UTP were also accepted. Thus, CitX functions as an
ACP nucleotidyltransferase (apo-ACP + NTP f NMP-ACP
+ PPi).
To answer the question of whether AMP-ACP is an
intermediate in the formation of holo-ACP or a byproduct
formed by CitX only in the absence of CitG, we established
an in vitro system that allowed the conversion of apo-ACP
into holo-ACP exclusively with purified components. The
identity of the prosthetic groups synthesized in vivo and in
vitro was confirmed by their identical behavior during
reversed phase HPLC. Moreover, the mass difference of apo-
ACP and in vitro synthesized holo-ACP corresponded exactly
to the calculated mass of the prosthetic group. For unknown
reasons, it was not possible to detect the tryptic peptide
carrying the entire prosthetic group by MALDI-TOF mass
spectrometry. By means of the in vitro system, we unequivo-
cally identified ATP and dephospho-CoA as sole precursors
of the prosthetic group and showed that CitG and CitX are
the only enzymes required for its synthesis. Remarkably,
ATP could not be replaced by CTP, GTP, or UTP in the
process of holo-ACP formation.
Attempts to convert AMP-ACP to holo-ACP by incubation
with CitG and dephospho-CoA failed completely (Figure 10).
Therefore, AMP-ACP is not an intermediate during the
formation of holo-ACP, but an artificial byproduct formed
only if the natural substrate of CitX is absent. Taken together,
our results clearly indicate that the first step in the formation
of holo-ACP is the synthesis of a precursor of the prosthetic
group from ATP and dephospho-CoA catalyzed by CitG.
According to the structure of the prosthetic group, this
precursor presumably is 2′-(5′′-triphosphoribosyl)-3′-dephos-
pho-CoA. In this reaction, ATP cannot be replaced by CTP,
GTP, or UTP. In the second step, the prosthetic group
precursor and apo-ACP are converted to holo-ACP and
pyrophosphate in a CitX-catalyzed reaction. Preliminary
experiments strongly support this pathway; we have isolated
FIGURE 9: Reversed phase HPLC of the prosthetic group obtained
after alkaline treatment of purified E. coli citrate lyase (A) and of
the putative holo-ACP formed in vitro by incubation of apo-ACP
with CitG, CitX, ATP, and dephospho-CoA (B). The samples were
treated with 0.1 M NaOH for 30 min at 65 °C to cleave off the
prosthetic group. After pH adjustment to about 5 by HCl addition
and removal of the precipitated protein by centrifugation, the
compounds cleaved off were subjected to HPLC analysis. For
detection, the UV absorption at 254 nm was measured.
FIGURE 10: Nonconversion of AMP-ACP into holo-ACP. Apo-
ACPHis (22 íM) was incubated at room temperature with CitXStrep
(5 íM) and ATP (1 mM). After 30 min, the assay mixture was
split, and one half was supplemented with CitGHis (4 íM) and
dephospho-CoA (1 mM) and the other half with CitGHis (4 íM)
only. The two mixtures were incubated for an additional 30 min.
Samples were taken immediately after the start of the reaction with
ATP (lane 2), 30 min later (lane 3), and 30 min after the addition
of CitGHis and dephospho-CoA (lane 4) or of CitGHis only (lane
5). The samples were mixed with SDS sample buffer and subjected
to SDS-PAGE. Lane 1 contained a protein standard. The gel was
stained with Coomassie brilliant blue.
Citrate Lyase Prosthetic Group Biosynthesis Biochemistry, Vol. 39, No. 31, 2000 9447
by HPLC a compound that is formed in vitro by CitG from
ATP and dephospho-CoA, and we showed that this com-
pound and apo-ACP are subsequently converted to holo-ACP
by CitX.
Since the E. coli citX gene can complement the K.
pneumoniae citCDEFG genes in the formation of an active
citrate lyase, it is obvious that also K. pneumoniae must
possess a citX-like gene. The fact that it is not part of the
citCDEFG cluster might be accidental, but could also reflect
the fact that transcriptional regulation of the citX gene differs
from that of the citC operon (21, 22). Attempts to clone the
K. pneumoniae citX gene by heterologous hybridization with
an E. coli citX probe or by PCR with degenerated primers
were not successful (data not shown). However, a search
with the E. coli CitX protein against the sequences available
from the K. pneumoniae strain MGH78578 genome sequenc-
ing project performed at the Washington University School
of Medicine (St. Louis, MO; http://genome.wustl.edu/gsc/
Projects/bacterial/klebsiella/klebsiella.shtml) revealed the
presence of a sequence encoding a putative CitX protein.
Experiments are in progress to clone the corresponding
region by PCR from the K. pneumoniae strain (ATCC13882)
used in our studies and to analyze the regulation of the
putative citX gene and the function of its protein product.
In the citrate lyase gene clusters of H. influenzae, L.
mesenteroides, and L. paramesenteroides, citX is not a
separate gene but fused with citG, forming its 5′-terminal
part (Figure 2). The 180 N-terminal amino acids of these
extended CitG proteins are 26-30% identical to those of
CitX from E. coli (Figure 11). According to our results, the
CitG proteins from H. influenzae, L. mesenteroides, and L.
paramesenteroides are bifunctional enzymes. The finding that
CitX and CitG are fused in some bacteria underlines the fact
that these proteins act in concert. One can therefore envisage
that the prosthetic group precursor is not released by CitG,
but immediately captured by CitX and transferred to apo-
ACP.
The 2′-(5′′-phosphoribosyl)-3′-dephospho-CoA prosthetic
group is not unique to citrate lyase, but also occurs in
citramalate lyase and malonate decarboxylase. Analysis of
the gene clusters for malonate decarboxylase revealed that
madG from M. rubra (41) and mdcB from K. pneumoniae
(42), Pseudomonas putida (43), and A. calcoaceticus (19)
encode proteins whose sequences are 34-37% identical to
that of CitG from K. pneumoniae. None of these proteins
had an N-terminal extension that was similar to CitX, and
also none of the sequences of the other mad and mdc gene
products were unequivocally similar to that of CitX. How-
FIGURE 11: Sequence alignment of the N-terminal portions of the CitG proteins from H. influenzae (Hi), L. mesenteroides (Lm), and L.
paramesenteroides (Lp) with the CitX protein of E. coli (Ec). Note that the H. influenzae CitG protein used in this alignment contains 49
additional amino acids at the N-terminus compared to Swissprot database entry P44458. The sequence shown here starts at a TTG codon
located 181 bp downstream of the citF stop codon, whereas the P44458 sequence starts at a GGT codon located 328 bp downstream of citF.
FIGURE 12: Alignment of a conserved sequence motif identified
in enzymes with proven (CitX and GlnE) or proposed protein
adenylyltransferase activity, i.e., citrate lyase apo-ACP ATase (CitX
and CitG), malonate decarboxylase apo-ACP ATase (MdcG and
MadK), and glutamine synthetase ATase (GlnEC, C-terminal
adenylylation domain, and GlnEN, N-terminal deadenylylation
domain). The strictly conserved aspartate residues and the highly
conserved residues within the CitX family are shown in bold. The
members in quotation marks were obtained by TBLASTN searches
(46) of unfinished genome projects (http://www.ncbi.nlm.nih.gov/
Microb_blast/unfinishedgenome.html), and thus, their sequence and
designation are preliminary: Aa, Actinobacillus actinomycetem-
comitans; Ac, A. calcoaceticus; Ec, E. coli; Ef, Enterococcus
faecalis; Hi, H. influenzae; Kp, K. pneumoniae; Lm, L. mesenteroi-
des; Lp, L. paramesenteroides; Mr, M. rubra; Mt, Mycobacterium
tuberculosis; Pp, P. putida; Sp, Streptococcus pyogenes; St,
Salmonella typhi; Vc, Vibrio cholerae.
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ever, the proteins encoded by madK from M. rubra and by
mdcG from K. pneumoniae, P. putida, and A. calcoaceticus
may represent the functional equivalents to the E. coli CitX
protein, since they contain one short amino acid stretch that
is similar to CitX and, importantly, also to glutamine
synthetase adenylyltransferase, the glnE gene product (44).
GlnE, a central regulator of nitrogen assimilation in entero-
bacteria and several other bacterial species (ref 44 and
references therein), is the best-studied example of enzymes
that adenylylate other proteins. It possesses two catalytic
activities, i.e., the ATP-dependent adenylylation of a specific
tyrosine residue of glutamine synthetase (EC 6.3.1.2) with
the concomitant formation of pyrophosphate and the Pi-
dependent deadenylylation with the concomitant formation
of ADP. It was recently shown for E. coli GlnE (945 amino
acids) that the adenylylation activity resides on the C-terminal
domain, whereas the deadenylylation activity resides on the
N-terminal domain (45).
In Figure 12, an alignment of the conserved amino acid
stretch is shown, including sequences from unfinished
genome projects (http://www.ncbi.nlm.nih.gov/BLAST/un-
finishedgenome.html). It is evident that the DXD motif is
strictly conserved and that MadK, MdcG, and MdcE are
more similar to GlnE than to the CitX family. Although the
functional significance of this amino acid stretch is not yet
known, the motif G/A-R-L-X-D-L/I-D-V could represent a
signature sequence for proteins with citrate lyase apo-ACP
adenylyltransferase activity. The low level of overall se-
quence identity of MdcG and MadK to CitX (<22%) can
be explained by the fact that their substrates, i.e., the apo-
ACPs of malonate decarboxylase and citrate lyase, also
contain only limited regions with sequence identity (<26%).
Parallel to our work on citrate lyase, it was shown that the
synthesis of the K. pneumoniae malonate decarboxylase holo-
ACP is dependent on MdcB and MdcG, supporting the
proposed functional equivalence of CitX and MdcG (S.
Hoenke, M. Wild, and P. Dimroth, unpublished results).
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